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Abstract 
Background: 
Rising cirrhosis incidence and mortality in the United Kingdom has been attributed 
predominantly to excess alcohol consumption. However, metabolic risk factors such 
as type 2 diabetes and obesity may also be important.  
 
Aim:  
To screen at-risk individuals in general practice for undetected cirrhosis using 
transient elastography and study the risk factors underlying these cases. 
 
Methods: 
The study was undertaken in 4 general practices (adult patient population 20,868) 
between February 2012 and September 2014. Patients with defined risk factors for 
chronic liver disease (hazardous alcohol use and/or type 2 diabetes) were identified 
from the General Practice electronic records and invited for transient elastography. 
Elevated liver stiffness was defined as ≥8 kilopascals. Cirrhosis was confirmed by 
established histological, radiological and biochemical methods. 
 
Results: 
2,368 patients were invited for transient elastography and 899/919 who attended 
(97.8%) had valid measurements. Of these 230 patients had elevated liver stiffness 
(25.6%) and 27 had cirrhosis (2.9%). Risk factors for new cirrhosis diagnoses were 
obesity and/or type 2 diabetes in 16 patients (59.3%), alcohol alone in 3 (11.1%) and 
both alcohol and obesity and/or diabetes in 8 (29.6%). Presence of cirrhosis was 
significantly increased in obese patients with type 2 diabetes or hazardous alcohol 
use compared to non-obese (odds ratio 9.4 (95% CI 2.2-40.9) and 5.6 (95% CI 1.6-
19.7) respectively). 
 
Conclusions: 
The number of new cases of cirrhosis diagnosed clearly demonstrates that existing 
estimates of prevalence are likely to be gross underestimates. Obesity was an 
important risk factor for cirrhosis within both alcohol users and diabetics.   
 
ClinicalTrials.gov registration: NCT02037867 
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Introduction: 
Chronic liver disease continues to be a significant public health burden. In England, 
diagnosed cirrhosis incidence has increased by 50.6% between 1998 and 20091, 
and subsequently cirrhosis is now the third commonest cause of premature mortality 
in persons aged 20-542. Population level alcohol consumption is still considered the 
major driver of liver-related mortality, and up to 62% of detected cirrhosis cases in 
the population are attributed to alcoholic liver disease (ALD)1,3. However, the rising 
population prevalence of metabolic syndrome risk factors means that non-alcoholic 
fatty liver disease (NAFLD) and related cirrhosis are becoming a more significant 
issue. Obesity prevalence in the United Kingdom has risen by 54% in men and 65% 
in women between 1993 and 2012, and the prevalence of type 2 diabetes is forecast 
to double between 2000 and 2030. Non-alcoholic fatty liver disease is therefore likely 
to become the leading cause of liver cirrhosis in the near future, and indeed in the 
USA NAFLD has already overtaken alcoholic liver disease as a cause of listing for 
liver transplantation4. Several studies have demonstrated the important synergism 
between body mass index and alcohol consumption, and the increased risk of 
progressive fibrosis5, cirrhosis diagnoses6 and liver-related death7,8. However, as 
NAFLD is discounted as a diagnosis in the presence of a specific cut-off of alcohol 
consumption (such as a weekly consumption of >14 units in women and >21 units in 
men), all cirrhosis in those with an alcohol consumption above the cut-off will be 
coded as alcohol related cirrhosis9. The overall impact of obesity, type 2 diabetes 
and other metabolic risk factors on cirrhosis incidence and liver-related outcomes is 
therefore likely to be greatly underestimated by current practice. 
We have previously demonstrated that a community based service using transient 
elastography (TE) can detect appreciable quantities of previously unrecognised liver 
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disease among people with hazardous alcohol use and people with Type 2 
diabetes10. We extended this study with additional recruitment, to study the 
association of alcohol and metabolic risk factors with chronic liver disease in a 
community setting. The aims of the current study are to characterise new clinically 
significant liver disease and cirrhosis within the screened population, and to identify 
the risk factors associated with elevated liver stiffness and cirrhosis. 
Materials and Methods: 
Study Setting 
This was a cross-sectional study with recruitment from four general medical 
practices in Nottingham, United Kingdom. Of these, 2 primary care medical practices 
were located in an affluent suburban borough, whilst the remaining 2 practices were 
situated in predominantly deprived areas of the City of Nottingham District. The study 
period was 31 months from February 2012 to September 2014. All practices utilised 
the SystmOne general practice records system (TPP, United Kingdom) which 
facilitates live recording of clinical, anthropometric and biochemical patient data. 
Data is prospectively entered during all patients’ primary care appointments with 
General Practitioners and Practice Nurses. The same database is used for patients’ 
standard clinical care. Data is stored as searchable numeric data or prospectively 
coded with ‘Read Codes’ (clinical encoding of parameters including patient 
demographics, diagnoses, clinical signs and laboratory test results). The ‘Read 
Codes’ are based on electronic clinical management systems, in which the primary 
care clinician selects codes to record directly into the computerised medical record 
system. Local regulatory approval was obtained from the Leicester Research Ethics 
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Committee (study identification 13/EM/0123), and written informed consent was 
gained from patients.  
Patient Selection 
Patient selection for the current study has been previously published10. Briefly, adult 
patients (defined as aged 18 years or older) with selected risk factors for lifestyle 
related chronic liver disease were identified directly from the general medical 
practice electronic patient records. The electronic record search was performed at 
the commencement of the study. The studied risk factors were:  
 
a) Hazardous alcohol use – this was defined as presence of any of i) >14 units per 
week ethanol consumption for women or >21 units per week ethanol consumption for 
men, ii) alcohol AUDIT questionnaire score ≥811 or iii) presence of Read codes 
related to hazardous, harmful or dependent alcohol consumption. Patients were not 
included as hazardous alcohol consumers if alcohol consumption data had not been 
recorded in the 5 years prior to study. 
 
b) Type 2 Diabetes – Presence of Read codes related to a diagnosis of type 2 
diabetes. 
 
In addition, 3% of the study patients from the 4 studied practices were patients with 
persistently elevated serum alanine aminotransferase (ALT) levels (>35IU/L for 
women, >45IU/L for men), who had neither hazardous alcohol intake nor type 2 
diabetes, and negative liver autoimmune and serological tests.  
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Patients were excluded from the study if i) there was definitive evidence of hepatic 
fibrosis or cirrhosis already identified from previous investigations, ii) there was a 
contraindication to transient elastography (pregnancy, indwelling cardiac device), iii) 
they had metastatic malignancy, iv) they were unable to consent to investigation due 
to significant cognitive impairment, or v) they were housebound and could not attend 
the community practice. In addition, patients who presented with symptoms of 
decompensated liver cirrhosis (e.g. jaundice, variceal bleeding, ascites) during the 
study period were excluded and instead triaged straight to urgent hospital-based 
care rather than being screened using TE in primary care. 
 
Liver Stiffness Measurement 
The methodology for invitation and screening of patients from the suburban medical 
practices has been published previously, and included an initial screening blood 
biomarker prior to transient elastography10. Patients from the inner city practices 
were invited directly for an appointment to undergo transient elastography. The scan 
was performed by one of three nurses, all of whom had received formal training in 
liver stiffness measurement and had previously performed more than two hundred 
liver stiffness acquisitions in the hospital setting. Our nurse led transient 
elastography service has been established since 2009 and we have published the 
evaluation of this service in 2012 showing only 5.3 % of scans were unreliable12.  
Patients were advised to be fasted for the examination13. Patients with a body mass 
index (BMI) of <35kg/m2 underwent TE examination with the Fibroscan FS402 
device (Echosens) M probe in the general practice setting. Due to a high risk of 
unreliable or failed liver stiffness acquisition with body mass index (BMI) measures 
above this threshold demonstrated in previous studies14, patients with a 
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BMI>35kg/m2, and those with an initial failed liver stiffness acquisition using the M 
probe, underwent transient elastography in the hospital using the Fibroscan FS502 
device XL probe. 
 
Liver stiffness acquisition failure was defined as inability to obtain 10 valid liver 
stiffness measurements. Participants with failure of liver stiffness acquisition were 
excluded from the analysis. A successful acquisition was deemed unreliable if liver 
stiffness was ≥7.1 kilopascals and the interquartile range/median ratio was greater 
than 0.3 as per manufacturer guidance15. A liver stiffness threshold of 8.0 kilopascals 
or greater was used to define elevated liver stiffness, and hence clinically significant 
liver disease, in keeping with a previous large general population study in France16 in 
which this cut-off was shown to be an accurate predictor of liver fibrosis on biopsy. 
The same liver stiffness threshold was used for patients with both alcohol and non-
alcohol related liver risk factor as although alcohol-related liver fibrosis potentially 
results in slightly higher liver stiffness results than NAFLD, a recent meta-analysis of 
previous hospital studies has shown good accuracy for predicting significant (F2) 
liver fibrosis in patients with alcoholic liver disease using very similar liver stiffness 
cutoffs17.  
 
Patients with elevated liver stiffness results, including high but unreliable 
acquisitions, were reviewed by a visiting consultant hepatologist in the community 
(one of authors SR, EW, MJ, GPA or ING). Alternative causes of chronic liver 
disease (e.g. viral and autoimmune liver disease) were tested for. In addition, at the 
clinical discretion of the reviewing hepatologist, further investigations including 
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ultrasonography, liver biopsy and endoscopy were arranged on a case-by-case 
basis.  
 
Following the transient elastography appointment, patient’s electronic primary care 
records were retrospectively examined to collect recent relevant clinical, 
anthropometric and laboratory test data (definitions of these risk factors are shown in 
Online Appendix 1). As waist circumference was not routinely measured, obesity 
was defined as the presence of body mass index≥30kg/m2. Subsequently, metabolic 
syndrome was defined according to the International Diabetes Federation definition 
as presence of obesity with 2 or more metabolic risk factors (hypertension, impaired 
fasting glucose or type 2 diabetes, raised triglycerides or lowered high density 
lipoprotein  cholesterol)18.  
Cirrhosis Detection and Associated Risk Factors 
Cirrhosis was diagnosed clinically at the discretion of the visiting consultant 
hepatologist. To increase the positive predictive value of cirrhosis diagnoses, given 
the need for future cirrhosis surveillance investigations, cirrhosis diagnoses were not 
based upon an elevated liver stiffness measurement alone. Rather cirrhosis 
diagnoses were assigned using elevated liver stiffness measures in combination with 
either histological evidence of cirrhosis, endoscopic evidence of portal hypertension 
or ultrasound evidence of cirrhosis or portal hypertension (i.e. nodular liver surface, 
splenomegaly or reversal of portal vein flow). Cirrhosis diagnoses were classified as 
alcoholic liver disease if hazardous alcohol use was present in the absence of 
obesity or type 2 diabetes, as non-alcoholic fatty liver disease in the presence of type 
2 diabetes or obesity, but without hazardous alcohol use, and as dual aetiology if a 
combination of hazardous alcohol use and type 2 diabetes or obesity was present. 
Page | 9  
 
The number and aetiology of cirrhosis diagnoses in the general practice population 
before study commencement were obtained by searching the electronic patient 
records.  
To evaluate the impact of the defined clinical and metabolic risk factors on the 
presence of significant liver disease, we compared the percentage of elevated liver 
stiffness and cirrhosis cases for patients with and without these risk factors. 
Subgroup analyses examining patients with hazardous alcohol use, type 2 diabetes 
and both hazardous alcohol and type 2 diabetes were performed.  
Statistics 
Statistical analysis was performed using Stata version 13.1 (StataCorp LP). 
Categorical data are presented as number (percentage). Continuous data are 
presented as medians (range) (as all were non-normally distributed). Demographic, 
anthropometric and laboratory test data were compared between patients with and 
without cirrhosis using the Mann-Whitney test as appropriate. Categorical variables 
were compared using chi-squared test, or Fisher’s exact test where appropriate.  
In order to further evaluate the association of clinical and metabolic risk factors with 
clinically significant liver disease, for those risk factors which were associated with 
both presence of elevated liver stiffness and cirrhosis we report univariate odds 
ratios and 95% confidence intervals comparing patients with and without these 
clinical features in each of our studied groups. 
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Results 
Study Population 
The total adult population in the studied primary care centres at commencement of 
the study was 20,868 patients (see table 1). Hazardous alcohol use was detected in 
1,438 patients (6.9%) and 1,007 patients (4.8%) had type 2 diabetes. There were 
2,368 individual patients with hazardous alcohol use or type 2 diabetes identified 
from the electronic patient record search, of whom 346 were excluded (see Figure 
1). Subsequently 919/2,022 patients (45.4%) attended the transient elastography 
appointment; 71.3% of eligible patients with type 2 diabetes attended whilst 30.7% of 
patients with hazardous alcohol use attended. Overall, 401 patients had hazardous 
alcohol use, 554 patients had type 2 diabetes (including 65 patients (7.1%) with both 
risk factors present), and 29 had raised ALT without either hazardous alcohol use or 
type 2 diabetes. Of note, of the hazardous alcohol use group, 17 (4.2% of the group) 
had subsequently become abstinent and a further 38 (9.5%) had moderated their 
alcohol intake to within recommended safe drinking limits prior to the time of TE.  
Compared to non-attenders, transient elastography appointment attenders were 
significantly less likely to be hazardous alcohol users (43.6% vs. 83.0%; p<0.001), 
significantly less likely to be male (65.7% vs. 71.7%; p=0.004) and were significantly 
older (mean age 59.1 years vs. 47.8 years; p<0.001). 
Elevated Liver Stiffness and Cirrhosis Diagnoses 
Successful liver stiffness results were obtained in 899 patients (97.8% of those 
undergoing transient elastography). Of these, 819 (91.1%) liver stiffness acquisitions 
were obtained using the M probe in the primary care setting, whilst the remaining 80 
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patients required an XL probe examination in the hospital setting. Unreliable liver 
stiffness acquisitions occurred in 44 patients (4.9%).  
Overall, elevated liver stiffness of ≥8 kilopascals was observed in 230 patients 
(25.6%). Elevated liver stiffness was present in 19.2% of patients with hazardous 
alcohol use, 31.5% of patients with type 2 diabetes, 37.5% of patients with both 
hazardous alcohol use and type 2 diabetes, and 45.3% of patients with raised ALT 
levels. On further testing a single case of primary biliary cholangitis in a patient with 
coexistent non-alcoholic steatohepatitis was identified. A large number of clinical and 
anthropometric risk factors were more prevalent in patients with elevated liver 
stiffness compared to normal liver stiffness values (see table 2). However, both 
hazardous alcohol use prevalence (47.3% vs. 32.6%; p<0.001) and median alcohol 
consumption (8 vs. 3 units of ethanol per week; p<0.001) were significantly lower in 
patients with elevated liver stiffness.  
Prior to study commencement, there were 23 diagnosed cases of liver cirrhosis in 
the population of the studied general practices who were excluded from study. All 
cases had been diagnosed on the basis of histological evidence of liver cirrhosis, or 
presentation to hospital with decompensated liver cirrhosis. Their cirrhosis 
aetiologies were alcoholic liver disease (14 patients), Hepatitis B or C (5), NAFLD (1) 
and other (3). 
During the study, 209 patients with elevated liver stiffness attended and were 
reviewed in hepatology clinics and 27 of these were newly diagnosed with liver 
cirrhosis during the study period (3% of valid liver stiffness results). This, therefore, 
more than doubled the number of cirrhosis diagnoses in the studied general 
practices. Cirrhosis was diagnosed in 2.8% of the overall study patients with 
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hazardous alcohol use, 3.7% of patients with type 2 diabetes, 7.7% of patients with 
both hazardous alcohol use and type 2 diabetes, and 5.6% of patients with raised 
ALT levels. Relevant clinical characteristics of these patients are displayed in Table 
3. Cirrhosis aetiologies were NAFLD in 16 patients (59.3% of newly detected 
cirrhosis cases), alcoholic liver disease in 3 patients (11.1%) and risk factors for both 
ALD and NAFLD in the remaining 8 patients (29.6%). Definitive evidence of portal 
hypertension was found in 4 patients on further investigation (3 patients with small 
varices and 1 patient with ascites) and features suggestive of portal hypertension 
observed in 6 others (5 patients with splenomegaly and 1 patient with portal vein flow 
reversal on ultrasonography).  
Compared to patients with normal liver stiffness, patients with cirrhosis had 
significantly greater prevalence of obesity (81.6% vs. 31.8%; p=<0.001), greater 
prevalence of metabolic syndrome (59.3% vs. 25.5%; p=0.002), and higher 
prevalence of raised ALT levels (33.3% vs 13.0%; p=0.006). Therefore, normal ALT 
values were seen in 66.7% of patients with cirrhosis. 
The total number of patients with cirrhosis was 50 following the study, when 
considering known patients with cirrhosis pre-study (23 patients) and additional new 
diagnoses detected due to the study (27 patients). Overall 20 out of 1,007 known 
patients with type 2 diabetes in the studied general practices (2%), and 25 out of 
1,438 known hazardous alcohol drinkers (1.7%) were known to have cirrhosis upon 
completion of the study. 
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Impact of Clinical Parameters on Elevated Liver Stiffness and Cirrhosis 
Diagnoses 
A comparison of the clinical and anthropometric factors associated with elevated 
liver stiffness in the subgroups of patients with hazardous alcohol use, type 2 
diabetes and both risk factors are displayed in Table 4. Variables associated with 
elevated liver stiffness in subgroups of patients with either hazardous alcohol use or 
type 2 diabetes were obesity ((44.0% vs. 20.3%; p<0.001) and (67.8% vs. 42.6%; 
p<0.001) respectively), body mass index measurement ((median BMI 28.7 vs. 25.7; 
p<0.001) and (median BMI 32.45 vs. 28.9; p<0.001) respectively), metabolic 
syndrome ((26.7% vs. 8.9%; p<0.001) and (63.7% vs. 42.9%; p<0.001) respectively) 
and raised ALT level ((33.3% vs. 13.3%; p<0.001) and (26.9% vs. 7.6%; p<0.001) 
respectively). In addition, BMI measurement was associated with elevated liver 
stiffness in patients with both hazardous alcohol use and type 2 diabetes (median 
BMI 32.75 vs. 28.05; p<0.001). Corresponding data for cirrhosis is not provided due 
to too small patient numbers with cirrhosis within the analysed subgroups. 
Given their association with both elevated liver stiffness and cirrhosis diagnoses in 
the overall study population (tables 2 and 4), the impact of obesity, metabolic 
syndrome and raised ALT on the diagnosis of elevated liver stiffness and cirrhosis 
diagnoses were evaluated further for subgroups of 391 patients with hazardous 
alcohol use, 543 patients with type 2 diabetes and 64 patients with both of these risk 
factors. 
Hazardous alcohol users with obesity were significantly more likely to have elevated 
liver stiffness than hazardous alcohol users without obesity (Odds Ratio 3.1; 95% CI 
1.8-5.3), as were those with hazardous alcohol use and the metabolic syndrome (OR 
3.7 (95% CI 2.0-7.1) or those with hazardous alcohol use and raised ALT levels (OR 
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3.3; 95% CI 1.8-5.8). Likewise patients with type 2 diabetes and obesity were 
significantly more likely to have elevated liver stiffness than non-obese patients with 
type 2 diabetes (OR 2.9; 95% CI 1.9-4.2), as were those with type 2 diabetes and  
the metabolic syndrome (OR 2.4; 95% CI 1.6-3.5) or those with type 2 diabetes and 
raised ALT levels (OR 4.5; 95% CI 2.7-7.5). No significant associations were seen in 
those patients with both hazardous alcohol use and type 2 diabetes for elevated liver 
stiffness (see Table 5a). 
Hazardous alcohol users with obesity were significantly more likely to be diagnosed 
with cirrhosis than non–obese hazardous alcohol users (odds ratio 5.6; 95% CI 1.6-
19.7; cirrhosis prevalence 7.3% vs. 1.4%), and similarly obese patients with type 2 
diabetes were more likely to be so diagnosed than non-obese patients with type 2 
diabetes (OR 9.4; 95% CI 2.2-40.9; 6.6% vs. 0.7%). Patients with hazardous alcohol 
use, type 2 diabetes and obesity had a cirrhosis prevalence of 13.3%, although this 
was not statistically significantly greater than patients with hazardous alcohol use 
and type 2 diabetes alone (OR 5.1; 95%CI 0.5-48.2). The associations with obesity 
are also displayed graphically in Figure 2. Patients with type 2 diabetes and the 
metabolic syndrome were significantly more likely to be diagnosed with cirrhosis than 
patients with type 2 diabetes without metabolic syndrome (OR 4.4; 95% CI 1.4-13.2; 
cirrhosis prevalence 6.0% vs. 1.4%). There were no significant associations between 
raised ALT levels and cirrhosis diagnoses in any of the studied groups (see table 
5b). 
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Discussion 
Key Findings 
The current study investigates cirrhosis detection and risk factors for liver disease in 
primary care using transient elastography. Following screening of 919 patients with 
hazardous alcohol use, type 2 diabetes or raised ALT levels, using Transient 
Elastography and subsequent confirmative investigations, we identified 27 previously 
undiagnosed cases of cirrhosis, to supplement the 23 cases of cirrhosis that had 
been previously detected in this population. Hazardous alcohol users were less likely 
to attend and when they did, had a lower risk of cirrhosis than did diabetics. 
Grouping by risk factor we found that of those screened due to type 2 diabetes, a 
history of alcohol misuse or both 3.7%, 2.8% and 7.7% respectively were diagnosed 
with cirrhosis. When the risk factors were combined this resulted in a greater “yield” 
of detecting cirrhosis.  For example, 6.6% of studied patients with both type 2 
diabetes and obesity were diagnosed with cirrhosis, whilst 13.3% of patients with a 
combination of hazardous alcohol use, type 2 diabetes and obesity were cirrhotic. 
Within each of these groups the risk of elevated liver stiffness was greater in patients 
with type 2 diabetes, metabolic syndrome or raised ALT. In those detected with 
cirrhosis, obesity was the critical factor, not ALT. For example, compared to non-
obese patients, obese patients with hazardous alcohol use were 5.6 times more 
likely to be diagnosed with liver cirrhosis and obese patients with type 2 diabetes 
were 9.4 times more likely to be cirrhotic.  
Strengths and Limitations 
Hitherto, this is one of the largest studies to evaluate the performance of transient 
elastography in screening populations for liver disease in a community setting with 
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targeted risk factors. This allows us to study how simple risk factors can be 
combined to improve the detection of significant liver disease. We selected all 
available subjects with the relevant risk factors who were fit for screening and did not 
already have a liver disease diagnosis, in an attempt to limit selection bias. To 
maximise the generalisability of our results patients were recruited from both 
suburban and inner city primary care practices to provide a representative mixture. A 
further strength we believe is the clinical confirmation of cirrhosis diagnoses, for 
which we used additional supportive radiological, histological and endoscopic 
evidence. Although recent guidance has suggested that a liver stiffness reading of 
greater than 15 kilopascals is strongly suggestive of compensated cirrhosis19, the 
positive predictive value of liver stiffness readings in the community may be lower 
than previous secondary care studies due to reduced disease prevalence. We 
therefore believe the cirrhosis diagnoses we have reported are robust. 
One of the limitations however is that only 45% of the eligible population underwent 
the transient elastography examination, although this is a greater response rate than 
the other major UK primary care liver stratification study thus far reported, which 
enrolled only 35% of patients defined as at risk from their alcohol consumption20. 
There was however a response bias with screening attenders being older, more 
female and with a differing proportion of hazardous alcohol use and type 2 diabetes 
than non-attenders. It is therefore difficult to predict the incremental increase of 
cirrhosis which would be diagnosed if everyone invited had attended. A further 
limitation is that as we targeted only type 2 diabetes and alcohol misuse as risk 
factors, though we have been able to show that obesity is an important co-factor in 
each, we are unable to assess whether it is an important risk factor in its own right. 
Based upon this it is likely that we have screened the highest risk patients with 
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obesity within the population, but we will have not detected patients with clinically 
significant liver disease and obesity alone as a risk factor.  
Comparison with other studies 
Previous systematic reviews have highlighted the accuracy of transient elastography 
for stratifying fibrosis stage in secondary care populations with non-alcoholic fatty 
liver disease21,22. Our own group recently published a systematic review of 19 prior 
studies which stratified primary care populations for risk of liver disease with non-
invasive biomarkers23. Variables reported to be independently associated with 
elevated liver stiffness or fibrosis included obesity and elevated body mass index 
measurements, both of which in the current study were associated with significantly 
higher risks of liver disease in each of our studied risk factor groups. Subsequent 
results published from the Rotterdam Study of 3,041 patients over 45 years of age 
screened for liver disease using transient elastography24 showed that both 
BMI>30kg/m2 and type 2 diabetes were significantly associated with liver stiffness 
≥8kPa (risk factor prevalence compared to normal liver stiffness was 37.7% vs. 
21.4% for obesity, and 33.7% vs 9.8% for type 2 diabetes, respectively).  Two large 
epidemiological studies from the United Kingdom have previously demonstrated the 
important synergism between body mass index and alcohol in predicting cirrhosis 
development and liver-related mortality7,8. For example, one was a long term follow-
up of 9,722 male workers from Scotland analysing the risk of liver-related mortality. 
Whilst mortality risk due to elevated body mass index (overweight or obese patients) 
was not significantly different from baseline (hazard ratio 1.29, 95% CI 0.60-2.80), 
and far less than risk attributable to alcohol (consumption ≥15 units per week) 
(hazard ratio 3.66, 95% CI 1.74-7.71), the interaction of both body mass index and 
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alcohol greatly exceeded the risk from either factor alone or the expected product of 
the two (hazard ratio 9.53, 95% CI 4.98-18.2)8.  
We found cirrhosis in 3.7% of the patients with type 2 diabetes we screened which is 
similar to previous studies which have used transient elastography in cohorts of type 
2 diabetes25-28. In addition, two studies of patients with type 2 diabetes screened in a 
hospital setting have detected a far greater prevalence of cirrhosis than the current 
study. In a study of 392 patients with type 2 diabetes, Sporea et al27 found that 
13.8% of their clinic cohort had liver stiffness measures of 10.3 kilopascals or greater 
suggestive of cirrhosis.  A large study of patients attending diabetes screening in 
hospital published by Kwok et al highlighted both the high liver disease prevalence 
and impact of obesity detected using transient elastography29. In this study; 8.1% of 
patients with type 2 diabetes and BMI<25kg/m2 had elevated liver stiffness 
consistent with advanced fibrosis compared to 35.4% of patients with BMI>30kg/m2. 
Also in this study 11.2% had liver stiffness >11.5 kilopascals (used as a cirrhosis cut-
off). The high cirrhosis prevalence detected in these two studies is likely to be 
explained by a comparatively low liver stiffness threshold to define cirrhosis coupled 
with the lack of second line confirmatory investigations.  
Recent studies have published results of patients with type 2 diabetes screened for 
liver disease in a primary care population16,30,31. Roulot et al30 studied 705 patients 
with type 2 diabetes in France. Similar to our study, 2.1% of patients were diagnosed 
with cirrhosis, defined using a liver stiffness threshold of 13 kilopascals. Importantly, 
the 13 kilopascals threshold had a 100% sensitivity and negative predictive value for 
histological cirrhosis in 47 patients undergoing liver biopsy, albeit a lower positive 
predictive value of 55.6%. This indicates the importance of additional clinical 
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parameters (such as laboratory parameters, ultrasonography and liver biopsy) for 
such patients prior to enrolling them to cirrhosis surveillance regimes. 
Implications 
In real life clinical practice, patients will have multiple risk factors for chronic liver 
disease. For example, within this study 44% of our population undergoing TE had 
two or more of hazardous alcohol use, type 2 diabetes or obesity. Given this, and the 
synergism of these risk factors that the study highlights we feel that strictly 
dichotomising patients with alcoholic liver disease and NAFLD on the basis of a 
specific cut-off of alcohol consumption may serve to mislead. In our study patients 
with hazardous alcohol use, type 2 diabetes and obesity had a cirrhosis prevalence 
of 13.3%, and elevated liver stiffness was seen in 46.7%. However, when 
considering type 2 diabetes as the only selection criteria the equivalent figures were 
3.7% and 31.5%. That the vast majority of significant liver disease detected was 
found in those with diabetes and/or obesity shows we think that alcohol alone is not 
likely to remain the cause of the majority of the emerging epidemic of liver disease in 
the United Kingdom in future. 
Given the high prevalence of both elevated liver stiffness and cirrhosis detected in 
patients with type 2 diabetes, in addition to proof of concept of screening such 
patients using transient elastography in primary care, we believe that formal 
screening for liver disease in type 2 diabetes should now be considered. In addition 
to lifestyle alterations, early detection will allow optimal medication management of 
these individuals with antidiabetic medication which will also treat non-alcoholic 
steatohepatitis, such as pioglitazone32 or liraglutide33,34.  One option to increase the 
cost efficacy of this is for selective screening and surveillance based upon the type 
and number of risk factors, to ensure a high pre-test probability of identifying 
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clinically significant liver disease. In this study we have demonstrated that both 
hazardous alcohol use and obesity are potentially useful markers of higher risk 
groups for this purpose. Further optimisation of community-based liver disease 
detection strategy is required, both in terms of initial risk factor selection, and 
whether the addition of other simple liver fibrosis tests to primary care algorithms 
improves the classification of liver fibrosis35. Such work though we feel is now a 
priority to enable the eventual roll out of selective screening to detect liver disease at 
an earlier stage. 
Summary  
Using Transient Elastography to selectively screen for liver disease in primary care, 
and referring in high risk patients to a hepatology clinic resulted in a more than 
doubling of the number of cirrhosis cases diagnoses in the studied population. The 
majority of newly identified cirrhosis cases had type 2 diabetes and obesity as risk 
factors (and therefore, presumably had non-alcoholic fatty liver disease).The risk of 
cirrhosis was far higher in those with multiple risk factors (hazardous alcohol use, 
obesity and type 2 diabetes). Focussing upon the combination of liver disease risk 
factors is likely to be the most effective way of designing cost effective investigation 
algorithms, and relevant interventions, for patients in primary care. 
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Tables 
 
Table 1. Baseline characteristics of total adult patient population 
(n=20,868) at studied General Practice (GP) sites  
Variable Suburban GP 
Patients 
(n=10,479) 
Inner City GP 
Patients 
(n=10,389) 
P Value 
Age (n%) 
- 18-30 years 
- 31-40 years 
- 41-50 years 
- 51-60 years 
- 61-70 years 
- 71-80 years 
->80 years 
 
2100 (20.4%) 
2469 (23.6%) 
1903 (18.2%) 
1331 (12.7%) 
1287 (12.3%) 
781 (7.5%) 
608 (5.8%) 
 
 
2640 (25.4%) 
2333 (22.5%) 
1986 (19.1%) 
1535 (14.8%) 
953 (9.2%) 
606 (5.8%) 
346 (3.3%) 
 
<0.001 
0.06 
0.08 
<0.001 
<0.001 
<0.001 
<0.001 
Male Gender n(%) 5131 (49.0%) 
 
5391 (51.2%) <0.001 
Body Mass Index n(%) 
- 25-29.9 
- ≥30 
- Missing values 
 
2835 (27.1%) 
1320 (12.6%) 
1363 (13.0%) 
 
4177 (40.2%) 
2527 (24.3%) 
995 (9.6%) 
 
<0.001 
<0.001 
<0.001 
Hazardous Alcohol 
Use n(%) 
658 (6.3%) 780 (7.5%) <0.001 
Type 2 Diabetes n(%) 390 (3.7%) 
 
617 (5.9%) <0.001 
Ischaemic Heart 
Disease n(%) 
423 (4.0%) 
 
406 (3.9%) 0.66 
Hypertension n(%) 1521 (14.5%) 
 
1356 (13.1%) 0.002 
Hyperlipidaemia n(%) 2117 (20.2%) 
 
1806 (17.4%) <0.001 
P value compares patients from Suburban primary care practices and Inner City practices; p 
values≤0.05 are statistically significant and are displayed in bold. GP = General Practice 
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Table 2. Clinical and laboratory test characteristics of 899 patients with successful 
liver stiffness measurement, comparing patients with normal liver stiffness (n=669) 
separately to  patients with elevated liver stiffness (n=230) and patients with liver 
cirrhosis (n=27)  
Variable Normal Liver 
Stiffness 
(n=669) 
Elevated 
Liver 
Stiffness 
(n=230) 
P Value* Cirrhosis 
 (n=27) 
P Value$ 
Age (years)  60.0 (48-69) 63.0 (52-70) 0.02 63.0 (55-67) 0.48 
Male Gender 
n(%) 
430 (74.4%) 161 (70.0%) 0.12 20 (74.1%) 0.36 
Body Mass 
Index (kg/m2)  
 27.4 (24.2-
30.9) 
31.6 (28.2-
35.3) 
<0.001 33.2 (30.4-
36.3) 
0.258 
Hazardous 
Alcohol Use 
n(%) 
316 (47.3%) 75 (32.6%) <0.001 11 (40.7%) 0.77 
Current alcohol 
(units/week) 
8 (0-28) 3 (0-24) 0.02 2 (0-42) 0.90 
Type 2 Diabetes 
n(%) 
371 (55.5%) 171 (74.4%) <0.001 20 (74.1%) 0.14 
Raised ALT 
n(%) 
87 (13.0%) 73 (31.7%) <0.001 9 (33.3%) 0.006 
Obesity n(%) 210 (31.8%) 140 (60.9%) <0.001 22 (81.5%) <0.001 
Ischaemic Heart 
Disease n(%) 
69 (10.3%) 38 (16.5%) 0.01 5 (18.2%) 0.291 
Hypertension 
n(%) 
269 (40.3%) 126 (54.8%) <0.001 14 (51.9%) 0.41 
Hyperlipidaemia 
n(%) 
433 (64.8%) 176 (76.5%) <0.001 16 (59.3%) 0.54 
Metabolic 
Syndrome n(%) 
170 (25.5%) 118 (51.3%) <0.001 16 (59.3%) 0.002 
Liver Stiffness 
Median (kPa) 
 5.1 (4.3-6.1) 11.2 (8.9-
14.9) 
<0.001 27.4 (21.3-
48.8)$ 
<0.001 
 
Normally distributed numerical variables are displayed as mean (standard deviation(SD)) and 
compared using the t test, non-normally distributed numerical variables are displayed as 
median(interquartile range) and compared using the Mann-Whitney test. Categorical variables are 
displayed as n(%) and compared using Fisher’s Exact test. P values ≤0.05 are displayed in bold. *=p 
value comparing patients with elevated liver stiffness and normal liver stiffness, $=p value comparing 
patients with cirrhosis and normal liver stiffness. ALT = alanine aminotransferase, AST = aspartate 
aminotransferase, kPa = kilopascals. 
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Table 3. Laboratory test, imaging and histopathology results of 27 patients newly diagnosed with 
cirrhosis during study  
Liver 
Disease 
Risk 
Factor* 
Age Liver 
Stiffness 
(kPa) 
Platelet 
Count 
(109/L) 
Clinical 
Features of 
CLD¥ 
Ultrasound 
Abnormality$ 
Histopathology Endoscopy 
Abnormality 
Obesity 64 11.7 323 H No Cirrhosis 
(NASH) 
No 
T2DM 
and 
Obesity€ 
67 14.7 214 H No Not Performed No 
T2DM 
and 
Obesity 
49 15.8 211 H No Cirrhosis 
(NASH) 
No 
Alcohol, 
T2DM 
And 
Obesity 
64 17.1 182 No Splenomegaly 
(17cm) 
Not Performed Not 
Performed 
Alcohol, 
T2DM 
and 
Obesity 
67 18.2 309 No No Cirrhosis 
(NASH) 
No 
Alcohol, 
Obesity 
and 
T2DM 
67 18.5 95 No Cirrhosis (nodular 
liver), 
Splenomegaly 
(14cm) 
Not Performed No 
T2DM 
and 
Obesity 
63 21.3 169 H Splenomegaly 
(16cm) 
Cirrhosis 
(NASH) 
No 
T2DM 
and 
Obesity 
55 21.3 260 S No Cirrhosis 
(NASH) 
No 
T2DM 
and 
Obesity 
68 24.0 143 No No Cirrhosis 
(NASH) 
No 
T2DM 
and 
Obesity  
72 26.4 274 H Cirrhosis (Coarse 
echotexture of the 
liver) 
Not Performed Not 
Performed  
Alcohol 
And 
Obesity 
58 27.0 123 H  Cirrhosis (Nodular 
liver) 
Not Performed No 
T2DM 
And 
Obesity 
67 27.0 131 S No Cirrhosis 
(NASH) 
No 
Alcohol 
and 
T2DM 
48 27.0 339 No No Cirrhosis 
(ASH/NASH) 
Grade 1 
Varices 
T2DM 65 27.4 235 No No Cirrhosis 
(NASH) 
No 
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T2DM 
and 
Obesity 
57 35.3 136 No Cirrhosis (Nodular 
liver) 
Cirrhosis 
(NASH) 
Not 
Performed 
T2DM 
and 
Obesity 
52 36.3 147 H,S Splenomegaly 
(17cm) 
Not Performed No 
Alcohol 38 42.9 169 S Cirrhosis (Nodular 
liver) 
Not Performed Not 
Performed 
T2DM 
and 
Obese 
58 44.3 116 H Cirrhosis (Coarse 
echotexture of the 
liver), 
splenomegaly 
(14cm) 
Cirrhosis 
(NASH) 
Grade 1 
Varices 
Alcohol 
and 
Obesity 
54 46.4 103 H,S Cirrhosis (Nodular 
liver) 
Not Performed No 
Alcohol, 
T2DM 
and 
Obesity 
63 46.4 151 H No Not Performed Not 
Performed 
T2DM 
And 
Obesity 
68 48.8 144 No Splenomegaly 
(13cm) 
Not Performed Not 
Performed 
T2DM 
And 
Obesity 
65 49.6 356 H No Not Performed PHG 
T2DM 
And 
Obesity 
75 50.5 109 No Cirrhosis (Coarse 
echotexture of the 
liver), 
Splenomegaly 
(14cm) 
Not Performed Not 
Performed 
Alcohol 55 52.3 81 H,S Cirrhosis (Nodular 
liver), Reversal of 
portal vein flow 
Not Performed Not 
Performed 
Alcohol 56 60.8 177 S Cirrhosis (Nodular 
liver) 
Not Performed No 
T2DM 
and 
Obesity 
73 72 260 No Cirrhosis (Nodular 
liver) 
Not Performed No 
Alcohol 
and 
Obesity 
49 75 139 S Cirrhosis (Nodular 
liver), Trace of 
ascites 
Not Performed Grade 1 
Varices 
 
*Patients with alcohol excess as risk factor without obesity or type 2 diabetes were assigned 
diagnosis of cirrhosis due to alcoholic liver disease. Patients with type 2 diabetes or obesity without 
alcohol excess were assigned diagnosis of cirrhosis due to NASH. ¥Clinical features of chronic liver 
disease (CLD) – H = hepatomegaly, S = spider naevi. $Ultrasound abnormality refers to features 
suggestive of liver cirrhosis, rather than non-specific findings e.g. echotexture consistent with fatty 
liver infiltration/steatosis. €Due to patient body mass index of 54 and difficulty with subsequent 
investigations, Enhanced liver fibrosis (ELF) score of 12.392 was used as confirmation of cirrhosis. 
kPa = kilopascals, NASH = non-alcoholic steatohepatitis, PHG = portal hypertensive gastropathy, 
T2DM = type 2 diabetes. 
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Normally distributed numerical variables are displayed as mean (standard deviation(SD)) and 
compared using the t test, non-normally distributed numerical variables are displayed as 
median(interquartile range) and compared using the Mann-Whitney test. Categorical variables are 
displayed as n(%) and compared using Fisher’s Exact test. P values ≤0.05 are displayed in bold. *= p 
value comparing normal and elevated liver stiffness in patients with hazardous alcohol use; ¥ = p 
value comparing normal and elevated liver stiffness in patients with type 2 diabetes; β= p value 
comparing normal and elevated liver stiffness in patients with both of these risk factors. ALT = alanine 
aminotransferase, kPa = kilopascals, LSM = liver stiffness measurement. 
Table 4. Clinical and laboratory test characteristics of 899 patients with successful liver stiffness 
measurement (LSM), comparing clinical features of patients with normal and elevated liver 
stiffness in risk factor groups of hazardous alcohol use (n=391), type 2 diabetes (n=542) and 
those with both hazardous alcohol use and type 2 diabetes (n=64) 
Variable Alcohol and 
Normal 
LSM 
(n=316) 
Alcohol 
and 
Elevated 
LSM (n=75) 
T2DM and 
Normal 
LSM 
(n=371) 
T2DM and 
Elevated 
LSM 
(n=171) 
Both risks 
and 
Normal 
LSM 
(n=40) 
Both risks 
and 
Elevated 
LSM 
(n=24) 
Age (years)  55 (43-64) 61 (52-66)* 64 (56-74) 65 (54-71) 64.5 (57.5-
72.5) 
63 (56-67) 
Male Gender 
n(%) 
238 (75.3%) 65 (86.7%) 221 
(59.6%) 
115 (67.3%) 35 (87.5%) 22 (91.7%) 
Body Mass 
Index (kg/m2)  
25.7 (22.8-
28.7) 
28.7 (26.5-
33.3)* 
28.9 
(25.9-
32.0) 
32.45 (29.0-
36.3)¥ 
28.05 (26.0-
31.7) 
32.75 
(27.85-
35.9)β 
Hazardous 
Alcohol Use 
n(%) 
----- ----- 40 
(10.8%) 
24 (14.0%) ----- ----- 
Current alcohol 
(units/week) 
28 (21-42) 30 (23-60) 0.5 (0-6) 1 (0-7) 25 (20-30) 29 (20.5-46) 
Type 2 Diabetes 
n(%) 
40 (12.7%) 24 (32.0%)* ----- ----- ----- ----- 
Raised ALT 
level n(%) 
42 (13.3%) 25 (33.3%)* 28 (7.6%) 46 (26.9%)¥ 4 (10.0%) 6 (25.0%) 
Obesity n(%) 63 (20.3%) 33 (44.0%)* 157 
(42.6%) 
116 
(67.8%)¥ 
16 (40.0%) 14 (58.3%) 
Ischaemic Heart 
Disease n(%) 
18 (5.7%) 10 (13.3%)* 55 
(14.8%) 
31 (18.1%) 5 (12.5%) 3 (12.5%) 
Hypertension 
n(%) 
78 (24.8%) 38 (50.7%)* 209 
(56.3%) 
101 (59.1%) 22 (55.0%) 16 (66.7%) 
Hyperlipidaemia 
n(%) 
143 (45.3%) 40 (53.3%) 318 
(85.7%) 
149 (87.1%) 34 (85.0%) 17 (70.8%) 
Metabolic 
Syndrome n(%) 
28 (8.9%) 20 (26.7%)* 157 
(42.3%) 
109 
(63.7%)¥ 
15 (37.5) 12 (50.0%) 
Liver Stiffness 
Median (kPa) 
4.8 (4.1-
5.75) 
10.9 (9.0-
15.7)* 
5.3 (4.4-
6.4) 
11.3 (9.0-
15.8) ¥ 
5.1 (4.4-6.4) 12.85 (9.1-
17.65) β 
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Table 5a. Odds ratios for presence of elevated liver stiffness comparing presence and absence of 
obesity, metabolic syndrome and raised ALT level in patients with hazardous alcohol use (n=391), type 2 
diabetes (n=543) or both hazardous alcohol and type 2 diabetes (n=64) 
Variable Hazardous Alcohol Use 
(n=391) 
Type 2 Diabetes (n=543) Hazardous Alcohol and Type 
2 Diabetes (n=64) 
 Exposed Non-
exposed 
OR 
(95%CI) 
Exposed Non-
exposed 
OR 
(95%CI) 
Exposed Non-
exposed 
OR 
(95%CI) 
Obesity  33/96 42/290 3.1 (1.8-
5.3) 
116/273 55/267 2.9 (1.9-
4.2) 
14/30 10/34 2.1 (0.8-
5.9) 
Metabolic 
Syndrome  
20/48 55/343 3.7 (2.0-
7.1) 
109/266 62/276 2.4 (1.6-
3.5) 
12/27 12/37 1.7 (0.6-
4.6) 
Raised 
ALT level 
25/67 
 
50/324 
 
3.3 (1.8-
5.8) 
 
46/74 125/469 4.5 (2.7-
7.5) 
6/10 18/54 3.0 (0.8-
12.0) 
Table 5b. Odds ratios for presence of cirrhosis comparing presence and absence of obesity, metabolic 
syndrome and raised ALT level in patients with hazardous alcohol use (n=391), type 2 diabetes (n=543) 
or both hazardous alcohol and type 2 diabetes (n=64) 
Variable Hazardous Alcohol Use 
(n=391) 
Type 2 Diabetes (n=543) Hazardous Alcohol and Type 
2 Diabetes (n=64) 
 Exposed Non-
exposed 
OR 
(95%CI) 
Exposed Non-
exposed 
OR 
(95%CI) 
Exposed Non-
exposed 
OR 
(95%CI) 
Obesity  7/96 4/290 5.6 (1.6-
19.7) 
18/273 2/268 9.4 (2.2-
40.9) 
4/30 1/34 5.1 (0.5-
48.2) 
Metabolic 
Syndrome  
3/48 8/343 2.8 (0.7-
10.9) 
16/266 4/277 4.4 (1.4-
13.2) 
3/27 2/27 2.2 (0.3-
14.1) 
Raised 
ALT level  
4/67 7/324 2.9 (0.8-
10.1) 
5/74 15/469 2.2 (0.8-
6.2) 
1/10 4/54 1.4 (0.1-
13.9) 
 
ALT = alanine aminotransferase; CI = confidence interval, OR = odds ratio; odds ratios reaching 
statistical significance are displayed in bold 
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Figure Legends 
Figure 1 – Flowchart of 2,368 patients identified with risk factor for chronic liver 
disease through the transient elastography screening pathway  
Figure 2 – Comparison of cirrhosis prevalence between obese and non-obese 
patients in risk factor groups of hazardous alcohol use (n=386), type 2 diabetes 
(n=541) and patients with both hazardous alcohol use and type 2 diabetes (n=64). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
